Is it just me, or is the market that CYC is targeting super small?
"Cyclopharm is initially targeting the 600,000 nuclear medicine imaging procedures for PE, a marketwhich it estimates to be approximately US$90 million per annum. Based on Cyclopharm’s experiencein the Canadian market and globally, the company reiterates expectations it can achieve a 50% shareof this market over the next 2 to 3 years, rising to in excess of an 80% share over a 3 to 5-year period."
Add to My Watchlist
What is My Watchlist?
